Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung CancerDeepa Rangachari, Daniel B Costa
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerDaniel B Costa, Susumu Kobayashi
Translational Cancer Research|January 8, 2019
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire diseaseDeepa Rangachari, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 16, 2012
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutationDaniel B Costa, Susumu Kobayashi
Therapeutic Advances in Medical Oncology|September 10, 2011
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesElizabeth M Gaughan, Daniel B Costa
Diabetes Care|June 28, 2006
Improvement of type 2 diabetes in a lung cancer patient treated with ErlotinibDaniel B Costa, Mark S Huberman
Translational Lung Cancer Research|January 23, 2016
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790MDaniel B Costa, Susumu S Kobayashi
Lung Cancer (Amsterdam, Netherlands)|May 26, 2006
Three-year survival in metastatic non-small cell lung cancer treated with gefitinibDaniel B Costa, Susan T Schumer
The Lancet. Oncology|July 19, 2011
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsHiroyuki Yasuda, Susumu Kobayashi, Daniel B Costa
Frontiers in Oncology|July 28, 2020
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?Kartik Sehgal, Daniel B Costa, Deepa Rangachari
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung CancerDeepa Rangachari, Daniel B Costa
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerDaniel B Costa, Susumu Kobayashi
Translational Cancer Research|January 8, 2019
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire diseaseDeepa Rangachari, Daniel B Costa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 16, 2012
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutationDaniel B Costa, Susumu Kobayashi
Therapeutic Advances in Medical Oncology|September 10, 2011
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesElizabeth M Gaughan, Daniel B Costa
Diabetes Care|June 28, 2006
Improvement of type 2 diabetes in a lung cancer patient treated with ErlotinibDaniel B Costa, Mark S Huberman
Translational Lung Cancer Research|January 23, 2016
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790MDaniel B Costa, Susumu S Kobayashi
Lung Cancer (Amsterdam, Netherlands)|May 26, 2006
Three-year survival in metastatic non-small cell lung cancer treated with gefitinibDaniel B Costa, Susan T Schumer
The Lancet. Oncology|July 19, 2011
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsHiroyuki Yasuda, Susumu Kobayashi, Daniel B Costa
Frontiers in Oncology|July 28, 2020
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?Kartik Sehgal, Daniel B Costa, Deepa Rangachari
Pageof 18